Tsai YF, et al. - This study was undertaken to determine if the prognoses between immunohistochemical (IHC) 3+ patients and IHC 2+/in situ hybridization (ISH)+ patients were different. For this investigation, researchers analyzed the clinicopathological information of 886 consecutive cases of human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. Using a multivariate Cox regression model, the influences of the patients’ age, cancer stage, hormone receptor status, and anti-HER2 treatment were adjusted. For patients with HER2-positive invasive breast cancer, HER2 IHC scores and HER2 copy numbers can provide prognostic information. Findings revealed that both IHC 3+ and IHC 2+ patients with high HER2 copy numbers had a better prognosis.